Evaluation of red blood cell and platelet antigen genotyping platforms (ID CORE XT / ID HPA XT) in routine clinical practice

Kirstin Finning, Radhika Bhandari, Fiona Sellers, Nicoletta Revelli, Maria Antonietta Villa, Eduardo Muñiz-Díaz, Núria Nogués

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. High-throughput genotyping platforms enable simultaneous analysis of multiple polymorphisms for blood group typing. BLOODchip® ID is a genotyping platform based on Luminex® xMAP technology for simultaneous determination of 37 red blood cell (RBC) antigens (ID CORE XT) and 18 human platelet antigens (HPA) (ID HPA XT) using the BIDS XT software. Materials and methods. In this international multicentre study, the performance of ID CORE XT and ID HPA XT, using the centres' current genotyping methods as the reference for comparison, and the usability and practicality of these systems, were evaluated under working laboratory conditions. DNA was extracted from whole blood in EDTA with Qiagen methodologies. Ninety-six previously phenotyped/genotyped samples were processed per assay: 87 testing samples plus five positive controls and four negative controls. Results. Results were available for 519 samples: 258 with ID CORE XT and 261 with ID HPA XT. There were three "no calls" that were either caused by human error or resolved after repeating the test. Agreement between the tests and reference methods was 99.94% for ID CORE XT (9,540/9,546 antigens determined) and 100% for ID HPA XT (all 4,698 alleles determined). There were six discrepancies in antigen results in five RBC samples, four of which (in VS, N, S and Doª) could not be investigated due to lack of sufficient sample to perform additional tests and two of which (in S and C) were resolved in favour of ID CORE XT (100% accuracy). The total hands-on time was 28-41 minutes for a batch of 16 samples. Compared with the reference platforms, ID CORE XT and ID HPA XT were considered simpler to use and had shorter processing times. Discussion. ID CORE XT and ID HPA XT genotyping platforms for RBC and platelet systems were accurate and user-friendly in working laboratory settings.

Original languageEnglish
Pages (from-to)160-167
Number of pages8
JournalBlood Transfusion
Volume14
Issue number2
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Human Platelet Antigens
Blood Platelets
Erythrocytes
Antigens
Blood Grouping and Crossmatching
Blood Group Antigens
Edetic Acid
Multicenter Studies
Software
Alleles
Technology
DNA

Keywords

  • BLOODchip® ID
  • Genotyping
  • Platelets
  • Red blood cells

ASJC Scopus subject areas

  • Hematology
  • Immunology and Allergy

Cite this

Evaluation of red blood cell and platelet antigen genotyping platforms (ID CORE XT / ID HPA XT) in routine clinical practice. / Finning, Kirstin; Bhandari, Radhika; Sellers, Fiona; Revelli, Nicoletta; Villa, Maria Antonietta; Muñiz-Díaz, Eduardo; Nogués, Núria.

In: Blood Transfusion, Vol. 14, No. 2, 01.03.2016, p. 160-167.

Research output: Contribution to journalArticle

Finning, Kirstin ; Bhandari, Radhika ; Sellers, Fiona ; Revelli, Nicoletta ; Villa, Maria Antonietta ; Muñiz-Díaz, Eduardo ; Nogués, Núria. / Evaluation of red blood cell and platelet antigen genotyping platforms (ID CORE XT / ID HPA XT) in routine clinical practice. In: Blood Transfusion. 2016 ; Vol. 14, No. 2. pp. 160-167.
@article{4eda2f4fad084a0786dc3132aa17a64f,
title = "Evaluation of red blood cell and platelet antigen genotyping platforms (ID CORE XT / ID HPA XT) in routine clinical practice",
abstract = "Background. High-throughput genotyping platforms enable simultaneous analysis of multiple polymorphisms for blood group typing. BLOODchip{\circledR} ID is a genotyping platform based on Luminex{\circledR} xMAP technology for simultaneous determination of 37 red blood cell (RBC) antigens (ID CORE XT) and 18 human platelet antigens (HPA) (ID HPA XT) using the BIDS XT software. Materials and methods. In this international multicentre study, the performance of ID CORE XT and ID HPA XT, using the centres' current genotyping methods as the reference for comparison, and the usability and practicality of these systems, were evaluated under working laboratory conditions. DNA was extracted from whole blood in EDTA with Qiagen methodologies. Ninety-six previously phenotyped/genotyped samples were processed per assay: 87 testing samples plus five positive controls and four negative controls. Results. Results were available for 519 samples: 258 with ID CORE XT and 261 with ID HPA XT. There were three {"}no calls{"} that were either caused by human error or resolved after repeating the test. Agreement between the tests and reference methods was 99.94{\%} for ID CORE XT (9,540/9,546 antigens determined) and 100{\%} for ID HPA XT (all 4,698 alleles determined). There were six discrepancies in antigen results in five RBC samples, four of which (in VS, N, S and Doª) could not be investigated due to lack of sufficient sample to perform additional tests and two of which (in S and C) were resolved in favour of ID CORE XT (100{\%} accuracy). The total hands-on time was 28-41 minutes for a batch of 16 samples. Compared with the reference platforms, ID CORE XT and ID HPA XT were considered simpler to use and had shorter processing times. Discussion. ID CORE XT and ID HPA XT genotyping platforms for RBC and platelet systems were accurate and user-friendly in working laboratory settings.",
keywords = "BLOODchip{\circledR} ID, Genotyping, Platelets, Red blood cells",
author = "Kirstin Finning and Radhika Bhandari and Fiona Sellers and Nicoletta Revelli and Villa, {Maria Antonietta} and Eduardo Mu{\~n}iz-D{\'i}az and N{\'u}ria Nogu{\'e}s",
year = "2016",
month = "3",
day = "1",
doi = "10.2450/2015.0124-15",
language = "English",
volume = "14",
pages = "160--167",
journal = "Blood Transfusion",
issn = "1723-2007",
publisher = "Edizioni SIMTI",
number = "2",

}

TY - JOUR

T1 - Evaluation of red blood cell and platelet antigen genotyping platforms (ID CORE XT / ID HPA XT) in routine clinical practice

AU - Finning, Kirstin

AU - Bhandari, Radhika

AU - Sellers, Fiona

AU - Revelli, Nicoletta

AU - Villa, Maria Antonietta

AU - Muñiz-Díaz, Eduardo

AU - Nogués, Núria

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background. High-throughput genotyping platforms enable simultaneous analysis of multiple polymorphisms for blood group typing. BLOODchip® ID is a genotyping platform based on Luminex® xMAP technology for simultaneous determination of 37 red blood cell (RBC) antigens (ID CORE XT) and 18 human platelet antigens (HPA) (ID HPA XT) using the BIDS XT software. Materials and methods. In this international multicentre study, the performance of ID CORE XT and ID HPA XT, using the centres' current genotyping methods as the reference for comparison, and the usability and practicality of these systems, were evaluated under working laboratory conditions. DNA was extracted from whole blood in EDTA with Qiagen methodologies. Ninety-six previously phenotyped/genotyped samples were processed per assay: 87 testing samples plus five positive controls and four negative controls. Results. Results were available for 519 samples: 258 with ID CORE XT and 261 with ID HPA XT. There were three "no calls" that were either caused by human error or resolved after repeating the test. Agreement between the tests and reference methods was 99.94% for ID CORE XT (9,540/9,546 antigens determined) and 100% for ID HPA XT (all 4,698 alleles determined). There were six discrepancies in antigen results in five RBC samples, four of which (in VS, N, S and Doª) could not be investigated due to lack of sufficient sample to perform additional tests and two of which (in S and C) were resolved in favour of ID CORE XT (100% accuracy). The total hands-on time was 28-41 minutes for a batch of 16 samples. Compared with the reference platforms, ID CORE XT and ID HPA XT were considered simpler to use and had shorter processing times. Discussion. ID CORE XT and ID HPA XT genotyping platforms for RBC and platelet systems were accurate and user-friendly in working laboratory settings.

AB - Background. High-throughput genotyping platforms enable simultaneous analysis of multiple polymorphisms for blood group typing. BLOODchip® ID is a genotyping platform based on Luminex® xMAP technology for simultaneous determination of 37 red blood cell (RBC) antigens (ID CORE XT) and 18 human platelet antigens (HPA) (ID HPA XT) using the BIDS XT software. Materials and methods. In this international multicentre study, the performance of ID CORE XT and ID HPA XT, using the centres' current genotyping methods as the reference for comparison, and the usability and practicality of these systems, were evaluated under working laboratory conditions. DNA was extracted from whole blood in EDTA with Qiagen methodologies. Ninety-six previously phenotyped/genotyped samples were processed per assay: 87 testing samples plus five positive controls and four negative controls. Results. Results were available for 519 samples: 258 with ID CORE XT and 261 with ID HPA XT. There were three "no calls" that were either caused by human error or resolved after repeating the test. Agreement between the tests and reference methods was 99.94% for ID CORE XT (9,540/9,546 antigens determined) and 100% for ID HPA XT (all 4,698 alleles determined). There were six discrepancies in antigen results in five RBC samples, four of which (in VS, N, S and Doª) could not be investigated due to lack of sufficient sample to perform additional tests and two of which (in S and C) were resolved in favour of ID CORE XT (100% accuracy). The total hands-on time was 28-41 minutes for a batch of 16 samples. Compared with the reference platforms, ID CORE XT and ID HPA XT were considered simpler to use and had shorter processing times. Discussion. ID CORE XT and ID HPA XT genotyping platforms for RBC and platelet systems were accurate and user-friendly in working laboratory settings.

KW - BLOODchip® ID

KW - Genotyping

KW - Platelets

KW - Red blood cells

UR - http://www.scopus.com/inward/record.url?scp=84961640933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961640933&partnerID=8YFLogxK

U2 - 10.2450/2015.0124-15

DO - 10.2450/2015.0124-15

M3 - Article

AN - SCOPUS:84961640933

VL - 14

SP - 160

EP - 167

JO - Blood Transfusion

JF - Blood Transfusion

SN - 1723-2007

IS - 2

ER -